Topics:

FDA Panel Cancels HIV Drug Meeting

FDA Panel Cancels HIV Drug Meeting

ROCKVILLE, Md—The FDA has postponed a meeting of its Antiviral Drugs Advisory Committee that was to consider Rescriptor (delavirdine), a Pharmacia and Upjohn Co. drug for use in treating HIV infection. The agency said the postponement will allow time to incorporate results of additional study information that recently became available. The FDA said it will reschedule the meeting, but announced no date.


 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.